Literature DB >> 3994801

Pseudohyponatremia.

T C Aw, F L Kiechle.   

Abstract

Pseudohyponatremia should be distinguished from true hyponatremia lest injudicious therapy be instituted. Pseudohyponatremia is caused by a displacement of serum water by elevated concentrations of serum lipids or proteins. Only two (flame photometry and indirect potentiometry) of the three current methods available for measuring serum sodium involve sample dilution and may consequently produce spuriously low sodium values. The third method (direct potentiometry) involves no sample dilution, and sodium measurements are unaffected by hyperlipidemia and hyperproteinemia. As all three methods for sodium measurements may coexist in a clinical laboratory, it is important for the physician to be aware not only of the serum value but also the method employed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994801     DOI: 10.1016/0735-6757(85)90096-8

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  5 in total

1.  Plasma sodium measurements by direct ion selective methods in laboratory and point of care may not be clinically interchangeable.

Authors:  Brigit A Weld; Thomas J Morgan; Jeffrey J Presneill; Steven Weier; David Cowley
Journal:  J Clin Monit Comput       Date:  2016-09-28       Impact factor: 2.502

2.  Development of a Novel Quality Improvement Indicator Based on the Hemolysis Index.

Authors:  Eun Jin Lee; Miyoung Kim; Han Sung Kim; Min Jeong Park; Young Kyung Lee; Hee Jung Kang
Journal:  Ann Lab Med       Date:  2016-11       Impact factor: 3.464

3.  Pseudohyponatraemia secondary to hyperlipidaemia in obstructive jaundice.

Authors:  Samuel O Igbinedion; Sudha Pandit; Meher S Mavuram; Moheb Boktor
Journal:  BMJ Case Rep       Date:  2017-12-01

4.  Conivaptan and its role in the treatment of hyponatremia.

Authors:  Jalal K Ghali; Jareer O Farah; Suleiman Daifallah; Hassan A Zabalawi; Hammam D Zmily
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

5.  Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.

Authors:  Biff F Palmer; Amy D Rock; Emily J Woodward
Journal:  Drug Des Devel Ther       Date:  2016-01-18       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.